| Methods |
15‐day washout; 15‐day placebo run‐in; inclusion criteria= DBP 95‐120 mm Hg after run‐in; 4‐week double‐blind treatment |
| Participants |
Enalapril 20 mg: n=53(40 males,13 females); mean age=47.4 years; baseline supine SBP=161.4(13.0) mm Hg, DBP=103.3(6.3) mm Hg;
Placebo: n=47(31 males,16 females); mean age=46.8 years; baseline supine SBP=163.5(13.8) mm Hg, DBP=104.6(7.0) mm Hg |
| Interventions |
Enalapril 20 mg once daily;
Placebo |
| Outcomes |
Peak supine SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SD of change not reported, endpoint BP and SD reported; imputed endpoint SD for SD of change; BP data from Table I, p. 19; Jadad score=3; funding source= Merck Sharpe and Dohme |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
